My watch list
my.chemeurope.com  
Login  

NicOx



NicOx is a French pharmaceutical company. Its headquarters are at Sophia Antipolis. Louis Ignarro, corecipient of the 1998 Nobel Prize in Physiology or Medicine for demonstrating the signalling properties of nitric oxide, is a member of the scientific committee of the company.

The company focuses on the uses of the medical properties of nitric oxide. It is developing an anti-inflammatory drug, naproxcinod, of the CINOD (COX-inhibiting nitric oxide donator) class for the treatment of osteoarthritis. If clinical trials are successful, naproxcinod could replace Vioxx in 2010.

The market capitalisation of the company is $ 1.2 billion (April 2006). It is listed on Euronext, the French stock exchange and is part of the CAC Mid 100 stock market index. It will be part of the SBF 120 index from 18th June 2007. Oppenheimer Funds is its first shareholder with 25 % of its capital.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "NicOx". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE